Plasma Concentration and Excretion of Calcium-47, Strontium-85, Barium-133 and Radium-223 following Successive Intravenous Doses to a Healthy Man

Harrison, G. E.; Carr, T. E. F.; Sutton, Alice; Rundo, J.

doi:10.1038/209526b0

Cited by 35 publications

(12 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3) that the radioactivity accumulated in the skeleton with a preference for the osteoblastic metastases. Clearing was predominantly by the hepatobilliary/intestinal route and presumably with some renal elimination (27). In the six patients where gamma-camera scintigraphy was done, accumulation of 223 Ra was observed in skeletal lesions similar to that seen in diagnostic 99m Tc-methylene diphosphonate ( 99m Tc-MDP) bone scans.…”

Section: Resultsmentioning

confidence: 81%

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Nilsson

Larsen

Fosså

et al. 2005

Clinical Cancer Research

404

272

View full text Add to dashboard Cite

Purpose: The main goals were to study the safety and tolerability of the a-emitter radium-223 ( 223 Ra) in breast and prostate cancer patients with skeletal metastases. In addition, pain palliation was evaluated. Experimental Design: Fifteen prostate and 10 breast cancer patients enrolled in a phase I trial received a single i.v. injection of 223 Ra. Five patients were included at each of the dosages: 46, 93, 163, 213, or 250 kBq/kg and followed for 8 weeks. Palliative response was evaluated according to the pain scale of the European Organization for Research andTreatment of Cancer QLQ C30 questionnaire at baseline and at 1, 4, and 8 weeks after injection. Results: Weekly blood sampling during follow-up revealed mild and reversible myelosuppression with nadir 2 to 4 weeks after the injection. Importantly, for thrombocytes only grade 1toxicity was reported. Grade 3 neutropenia and leucopenia occurred in two and three patients, respectively. Mild, transient diarrhea was observed in 10 of the 25 patients. Nausea and vomiting was more frequently observed in the highest dosage group. Serum alkaline phosphatase decreased with nadir averages of 29.5% in females and 52.1% in males. Pain relief was reported by 52%, 60%, and 56% of the patients after 7 days, 4, and 8 weeks, respectively.

show abstract

Section: Resultsmentioning

confidence: 81%

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Nilsson

Larsen

Fosså

et al. 2005

Clinical Cancer Research

404

272

View full text Add to dashboard Cite

show abstract

“…VARIOUS parameters concerning the metabolism of 4 alkaline earth elements, Ca, Sr, Ba and Ra have been compared in man and in experimental animals (LLOYD, 1964;HARRISON et al, 1966;LINIECKI, 1971 ;MARSHALL et al, 1973). In the radionuclide toxicity program at the University of Utah (DOUGHERTY et al, 1962), beagles which were given 22aRa or and sacrificed at various times after injection have provided an opportunity to determine and compare the distribution for three of these elements (injected Ra and Sr and naturally occurring Ca).…”

Section: Introductionmentioning

confidence: 99%

Distribution of Injected 226Ra and 90Sr in the Beagle Skeleton

Lloyd¹,

Mays²,

Atherton³

1976

Health Physics

View full text Add to dashboard Cite

The 22sRa content of individual bones from nine adult beagles dying 1-2099 days after the injection of 0.163-10.6 pCi 226Ra/kg was determined by gamma-ray counting after the bones were sealed in cans and frozen. Similarly, the sOSr content of individual bones from two beagles dying at 1740 and 2256 days after the injection of about 100 pCi %r/kg was determined by p-counting of the ashed bones. Comparison of the QoSr/Ca ratios in bone samples from two dogs sacrificed 9 and 14 days after injection with those in corresponding bone samples from a dog dying 1448 days after injection showed that, for dogs injected as young adults, cortical bone initially takes up injected sOSr less avidly than does trabecular bone. Since cortical bone turns over more slowly, this marked difference in labelling is not seen at times long after injection. The fraction of retained skeletal radium accounted for by some bones appeared to be dependent upon time after injection. This relationship was statistically significant for thoracic vertebrae (negative slope) and for cervical vertebrae, hindpaws and forepaws (positive slope). In no case did the absolute value of the calculated slope exceed 1 % of the retained total skeletal radium/yr. There was a significant difference between the animals injected with about 10 pCi 226Ra/kg and those given less than about 4 pCi 226Ra/kg. This difference was apparent in the relative distribution of retained activity in bones containing much trabecular or much cortical bone at burden times of more than 1 month. We attribute this effect to radiation damage of the bone remodeling processes in the high-level dogs. A comparison of 2zsRa and gOSr distribution among bones of the skeleton following injection indicated that these alkaline earth elements deposit in a similar fashion.

show abstract

“…The renal clearance of strontium has been measured in human subjects who received an intravenous injection of a dose of SrCl 2 and is approximately 4-10 L/day and 2-3 times greater than renal calcium clearance (Blake et al 1986(Blake et al , 1989a(Blake et al , 1989bHarrison et al 1955Harrison et al , 1966aNewton et al 1990;Samachson 1966). Based on these estimates, the renal clearance of strontium is substantially less than the product of the glomerular filtration rate in humans (approximately 180-200 L/day) and the estimated rate of filtration of strontium, assuming that approximately 50% of the strontium in plasma is ultrafilterable (Harrison et al 1955).…”

Section: Health Effectsmentioning

confidence: 99%

Immune System Modifications Induced in a Mouse Model of Chronic Exposure to⁹⁰Sr

Synhaeve¹,

Musilli²,

Stéfani³

et al. 2016

Radiation Research

View full text Add to dashboard Cite

Plasma Concentration and Excretion of Calcium-47, Strontium-85, Barium-133 and Radium-223 following Successive Intravenous Doses to a Healthy Man

Cited by 35 publications

References 1 publication

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Distribution of Injected 226Ra and 90Sr in the Beagle Skeleton

Immune System Modifications Induced in a Mouse Model of Chronic Exposure to⁹⁰Sr

Contact Info

Product

Resources

About

Plasma Concentration and Excretion of Calcium-47, Strontium-85, Barium-133 and Radium-223 following Successive Intravenous Doses to a Healthy Man

Cited by 35 publications

References 1 publication

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Distribution of Injected 226Ra and 90Sr in the Beagle Skeleton

Immune System Modifications Induced in a Mouse Model of Chronic Exposure to90Sr

Contact Info

Product

Resources

About

Immune System Modifications Induced in a Mouse Model of Chronic Exposure to⁹⁰Sr